Cyclophosphamide-induced suppressor cells in mice: suppression of the antibody response in vitro and characterization of the effector cells. 1985

M Segre, and E Tomei, and D Segre

It was found earlier that nonspecific suppressor cells obtained from the spleen of mice injected with cyclophosphamide (Cy) at a dose of 200 mg/kg body wt are nonadherent, surface Ig negative, and Thy-1 negative. It is now reported that Cy-induced suppressor (Cy-S) cells suppress the in vitro primary and secondary humoral responses in a dose-dependent manner. Suppressor activity is a property of a low density cell that is found in the spleen from 5 to 11 days after Cy administration. Cy-S cells are negative for a number of T-cell markers and are nonadherent to plastic. They are not agglutinated by peanut agglutinin and do not acquire the Thy-1 antigen after treatment with thymosin, suggesting that they are not T-cell precursors. While NK activity was detected in the Cy-S cell preparations, this activity was removed by treatment with antibodies specific for the Qa-5 antigen and complement without affecting the suppressor activity. Cy-S cells are, therefore, distinct from B cells, T cells, NK cells, and macrophages.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008815 Mice, Inbred Strains Genetically identical individuals developed from brother and sister matings which have been carried out for twenty or more generations, or by parent x offspring matings carried out with certain restrictions. All animals within an inbred strain trace back to a common ancestor in the twentieth generation. Inbred Mouse Strains,Inbred Strain of Mice,Inbred Strain of Mouse,Inbred Strains of Mice,Mouse, Inbred Strain,Inbred Mouse Strain,Mouse Inbred Strain,Mouse Inbred Strains,Mouse Strain, Inbred,Mouse Strains, Inbred,Strain, Inbred Mouse,Strains, Inbred Mouse
D002448 Cell Adhesion Adherence of cells to surfaces or to other cells. Adhesion, Cell,Adhesions, Cell,Cell Adhesions
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D005260 Female Females
D006183 H-2 Antigens The major group of transplantation antigens in the mouse. H2 Antigens,Antigens, H-2,Antigens, H2,H 2 Antigens
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000917 Antibody Formation The production of ANTIBODIES by proliferating and differentiated B-LYMPHOCYTES under stimulation by ANTIGENS. Antibody Production,Antibody Response,Antibody Responses,Formation, Antibody,Production, Antibody,Response, Antibody,Responses, Antibody
D013154 Spleen An encapsulated lymphatic organ through which venous blood filters.
D013234 Stem Cells Relatively undifferentiated cells that retain the ability to divide and proliferate throughout postnatal life to provide progenitor cells that can differentiate into specialized cells. Colony-Forming Units,Mother Cells,Progenitor Cells,Colony-Forming Unit,Cell, Mother,Cell, Progenitor,Cell, Stem,Cells, Mother,Cells, Progenitor,Cells, Stem,Colony Forming Unit,Colony Forming Units,Mother Cell,Progenitor Cell,Stem Cell

Related Publications

M Segre, and E Tomei, and D Segre
April 1980, Cellular immunology,
M Segre, and E Tomei, and D Segre
August 1982, Immunopharmacology,
M Segre, and E Tomei, and D Segre
January 1981, Microbiology and immunology,
M Segre, and E Tomei, and D Segre
August 1992, Anti-cancer drugs,
M Segre, and E Tomei, and D Segre
April 1980, Cellular immunology,
M Segre, and E Tomei, and D Segre
November 1979, Journal of the National Cancer Institute,
M Segre, and E Tomei, and D Segre
May 1991, Diabetes research (Edinburgh, Scotland),
M Segre, and E Tomei, and D Segre
August 1982, Immunopharmacology,
M Segre, and E Tomei, and D Segre
February 1985, Journal of immunology (Baltimore, Md. : 1950),
M Segre, and E Tomei, and D Segre
January 1978, Annales d'immunologie,
Copied contents to your clipboard!